Glioblastoma,
the disease in numbers
Glioblastoma (GBM) affects 3.19 per 100’000 individuals in working age.
Following resection and pharmacological therapy, tumor relapses make the average prognosis less than two years.
GBM is a malignant brain cancer amongst the most lethal types of cancer. There is an urgent need for the development of novel therapeutic strategies that not only demonstrate enhanced efficacy but also affordability for patients and their families.
We develop therapeutic solutions for GBM patients
until their complete remission
Mission
The GlioGuard Drug Formulation
Our repurposed drugs formulation is effective in 40% of GBM cases with a combined short- and long-term treatment.
The GlioGuard Differential Diagnostics
Our precision diagnostics identifies GlioGuard responders from non-responders for a targeted and more effective therapeutic path.
Our Technology
About Us
Advisory
Board
The Advisory Board of Glioguard with its strong complementary competences operates to fullfill the mission of Glioguard in respect of diversity and gender-equality.
- Miran Skrap
- R.A.
- Anilkumar Dave
- Roberto Pugliese
- K.S.
Miran Skrap
Ronnie Andrews
Anilkumar Dave
Roberto Pugliese
NN
About Us
Pubblications
Li Y, Hernandez A, Trivino CA, Mortal S, Spada F, Spelat R, Cesselli D, Manini I, Cesca F, Skrap M , Menini A,Torre V
Accepted at Cancer Research
Xiao M, Li X, Song Q, Zhang Q, Lazzarino M, Cheng G, Ulloa Severino FP, Torre V.
Song Q, Pifferi S, Shi L, Chen C, Proietti Zaccaria R, Menini A, Cao J, Zhang Q,Torre V.
Xiao M, Ulloa Severino FP, Iseppon F, Cheng G,Torre V, Tang
Li X, Spelat R, Bartolini A, Cesselli D, Ius T, Skrap M, Caponnetto F, Manini I, Yang Y, Torre V
Xu J, Galvanetto N, Nie J, Yang Y, Torre V.
Spelat R, Jihua N, Sánchez Triviño CA, Pifferi S, Pozzi D, Manzati M, Mortal S, Schiavo I, Spada F, Zanchetta ME, Ius T, Manini I, Rolle IG, Parisse P, Millán AP, Bianconi G, Cesca F, Giugliano M, Menini A, Cesselli D, Skrap M, Torre V
Sanchez Trivino CA, Spelat R, Spada F, D’Angelo C, Manini I, Rolle IG, Ius T, Parisse P, Menini A, Cesselli D, Skrap M, Cesca F, Torre V
Under review
Contents
